Literature DB >> 34511612

Assessment of the Concordance Rate between Intraoperative Pathological Diagnosis and the Final Pathological Diagnosis of Spinal Cord Tumors.

Sosuke Muraoka1, Kentaro Yamane2, Haruo Misawa3, Tomoyuki Takigawa3, Tomoko Tetsunaga, Yoshiaki Oda3, Kazuo Nakanishi4, Toshifumi Ozaki1, Takehiro Tanaka5.   

Abstract

The intraoperative pathological diagnosis (IPD) plays an important role in determining the optimal surgical treatment for spinal cord tumors. The final pathological diagnosis (FPD) is sometimes different from the IPD. Here, we sought to identify the accuracy of the IPD of spinal cord tumors compared to the FPD. We retrospec-tively analyzed the cases of 108 patients with spinal cord tumors treated surgically in our institute; the IPD, FPD, mismatched cases, and concordance rate between the IPD and FPD were investigated. Five cases involved a mismatch between the IPD and FPD. The overall concordance rate was 95.4%, with 90.9% for extra-dural lesions, 98.5% for intradural extramedullary lesions, 84.2% for intramedullary lesions, and 100% for dumbbell-type tumors. The concordance rate of intramedullary lesions tended to be lower than that of other lesions (p = 0.096). A lower concordance rate was revealed for intramedullary lesions compared to the other lesions. Despite the IPD clearly remaining a valuable tool during operative procedures, surgeons should recog-nize the limitations of IPDs and make comprehensive decisions about surgical treatments.

Entities:  

Keywords:  final pathological diagnosis; concordance rate; intraoperative pathological diagnosis; spinal cord tumor

Mesh:

Year:  2021        PMID: 34511612     DOI: 10.18926/AMO/62397

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  1 in total

1.  Diagnostic Value of Emission Computed Tomography Combined with Computed Tomography for Metastatic Malignant Tumor of Spine.

Authors:  Feng Qin; Yapei Feng; Panpan Zhang; Yuemei Li; Weiqiang Fan
Journal:  Contrast Media Mol Imaging       Date:  2022-05-26       Impact factor: 3.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.